Neoplasia, Cancer, Outcomes analysis, Observer performance, Diagnostic procedure, MR, Pelvis, Oncology, Genital / Reproductive system male
J. Ash-Miles, H. M. A. OBrien, P. Charters, S. HALDAR; Bristol/UK
Methods and materials
All MP-MRI prostate scans performed between January and March 2018 for patients with a clinical suspicion of prostate cancer were reviewed.
Clinical suspicion of prostate cancer included those with an elevated age related serum PSA. Those with a known diagnosis of prostate cancer including those under active surveillance and those with a non-cancerous diagnosis such as infection were excluded.
The radiological MP-MRI images and report for each patient was reviewed including Prostate Imaging and Data Reporting System (PIRADS) score,
prostate density and 3-dimensional prostatic measurements.
The 5-point PIRADS is a radiology reporting prostate assessment category that determines the likelihood of clinically significant cancer on MP-MRI (see Figure 1).
The MP-MRI scans were reported by 4 dedicated radiologists who had 5 -20 years experience of reporting prostate MRI. We reviewed the pathology database to identify all patients who underwent prostate biopsy and data was collated including Gleason score and maximum cancer core length.